Get the Daily Brief
Latest Biotech News
Ultra‑mild methylation sequencing debuts: UMBS‑seq fixes bisulfite damage
Researchers unveiled UMBS‑seq, an 'ultra‑mild' DNA methylation sequencing method published in Nature Communications, addressing DNA damage and inconsistency problems in traditional bisulfite and...
Allen Institute launches Brain Knowledge Platform: 34M cells, AI models
The Allen Institute released the Brain Knowledge Platform (BKP), a consolidated AI‑driven resource standardizing over 34 million single-cell brain datasets across 22 species. The platform pairs...
Medicxi raises €500M fund to back asset‑centric biotech startups
Europe’s Medicxi closed a €500 million fifth fund to back asset‑centric biotech companies across development stages, the firm announced in a press release. The oversubscribed raise follows recent...
FDA clears Komzifti — Kura’s menin inhibitor approved for NPM1‑mutant AML
The FDA granted approval to ziftomenib (Komzifti) for relapsed or refractory acute myeloid leukemia with NPM1 mutations, marking Kura Oncology’s first approved therapy. The decision relied on the...
Pig kidney runs 61 days: Multi‑omics trace rejection and rescue
Researchers performed a genetically engineered pig kidney transplant into a brain‑dead human decedent and maintained graft function for 61 days while collecting serial samples for comprehensive...
Novartis’ GanLum hits Phase III goal — potential new tool against resistance
Novartis reported Phase III data showing its antimalarial combination GanLum (ganaplacide + lumefantrine) met the primary non‑inferiority endpoint versus the artemisinin‑based standard of care...
Lilly bets on brain shuttle: $2.6B ABL Bio pact advances CNS delivery
Eli Lilly signed a license and research agreement with ABL Bio to develop therapeutics using ABL’s Grabody‑B blood‑brain barrier (BBB)‑penetrating platform. The deal carries up to $2.6 billion in...
Pfizer closes Metsera buy — up to $10B deal ends bidding war
Pfizer completed its acquisition of obesity biotech Metsera in a deal worth as much as $10 billion, concluding a heated bidding contest that briefly involved Novo Nordisk. The transaction secures...
Day One buys Mersana — Emi‑Le ADC central to the deal
Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics in a deal that pays $25 per share upfront and up to additional contingent payments tied to Emi‑Le (emiltatug ledadotin), Mersana’s...
Korro pivots after failed RNA‑editing readout — mass layoffs follow
Korro Bio announced disappointing early clinical performance of its RNA‑editing candidate for alpha‑1 antitrypsin deficiency and cut roughly one‑third of its workforce while pivoting delivery...
FDA unveils plausible‑mechanism pathway — roadmap for bespoke gene edits
Senior FDA officials outlined a new regulatory approach—the so‑called plausible‑mechanism pathway—to accelerate approvals for deeply personalized gene‑editing therapies when randomized trials are...
Scientists probe neural‑organoid ethics — governance lags behind science
Neuroscience and bioethics experts convened to debate the ethical and societal implications of rapidly advancing human neural organoid and assembloid research. Participants, including Sergiu Pasca...
Neuro‑immunology and degrader startups raise nine‑figure rounds — Nilo and Gate scale
Two early‑stage biotechs closed sizable financings to advance novel modalities: Nilo Therapeutics launched with $101 million to translate neuro‑immune circuit biology into therapeutics that...
Komzifti cleared: Kura, Kyowa win FDA nod for NPM1‑mutant AML
The FDA approved ziftomenib (Komzifti), Kura Oncology and Kyowa Kirin’s oral menin inhibitor, for relapsed or refractory acute myeloid leukemia (AML) harboring NPM1 mutations. The decision was...
Pfizer seals Metsera takeover: Up to $10B obesity deal completes
Pfizer completed its acquisition of obesity biotech Metsera, finalizing a deal valued at up to $10 billion and ending a high‑stakes bidding contest with Novo Nordisk. The transaction transfers...
Pazdur named CDER head — FDA lays out plausible‑mechanism path for bespoke edits
The FDA appointed longtime oncology regulator Richard Pazdur to lead its Center for Drug Evaluation and Research (CDER) while senior officials publicly sketched a new regulatory approach to...
Multi‑omics map xenograft rejection: Antibodies and T cells drive pig‑to‑human kidney response
Two independent multi‑omic reports tracked immune events after a gene‑edited pig kidney was transplanted into a brain‑dead human recipient and maintained for 61 days. Researchers performed dense...
GanLum meets Phase 3 goal: Novartis positions new malaria therapy against resistance
Novartis reported Phase 3 data showing its experimental antimalarial GanLum (ganaplacide + lumefantrine) met the primary endpoint of noninferiority versus standard care across 1,688 patients in...
Day One buys Mersana: Emi‑Le ADC anchors back‑ended takeover
Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics in a deal structured with a modest upfront and significant milestone payments tied to clinical progress for Emi‑Le (emiltatug...
Allen Institute launches Brain Knowledge Platform: 34M brain‑cell datasets, AI models
The Allen Institute released the Brain Knowledge Platform (BKP), an open resource that standardizes and integrates more than 34 million brain‑cell datasets across species and modalities and pairs...